期刊
DRUG DISCOVERY TODAY
卷 25, 期 7, 页码 1262-1269出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2020.04.017
关键词
-
资金
- National Natural Science Foundation of China [81973173]
- Jiangsu Province Funds for Excellent Young Scientists [BK20170088]
- Fundamental Research Funds for the Central Universities [2632020TD021]
- Six Talent Peaks Project [YY-023]
- Qing Lan Project
- 333 Project of Jiangsu Province
Prolyl hydroxylase (PHD) inhibitors, such as roxadustat, can stabilize hypoxia-inducible factor (HIF)-2 alpha and induce erythropoietin (EPO) production under normal conditions. Roxadustat was recently approved as a first-in-class orally active drug for the treatment of renal anemia. In addition, it has garnered growing therapeutic interest for use against various diseases, such as carcinoma, neurological diseases, ocular diseases, and tissue and organ injuries. In this review, we systemically review target validation, hit identification, and further key clinical trials of roxadustat. The prospective clinical applications of PHD inhibitors are then discussed based on this marketed drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据